RETRACTED: Overexpression of long non-coding RNA TUG1 alleviates TNF-α-induced inflammatory injury in interstitial cells of Cajal (Retracted article. See vol. 27, pg. 5946, 2023)

被引:2
作者
Zhao, K. [1 ]
Tan, J-Y [1 ]
Mao, Q-D [1 ]
Ren, K-Y [1 ]
He, B-G [1 ]
Zhang, C-P [1 ]
Wei, L-Z [1 ]
机构
[1] Qingdao Univ, Dept Gastroenterol, Affiliated Hosp, Qingdao, Peoples R China
关键词
Irritable bowel syndrome; Interstitial cells of Cajal; Long non-coding RNA TUG1; MicroRNA-127; NF-kappa B pathway; Notch pathway; IRRITABLE-BOWEL-SYNDROME; NF-KAPPA-B; EXPRESSION; APOPTOSIS; LNCRNAS; PATHOGENESIS; PROTECTS; DISEASE; MICE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Irritable bowel syndrome (IBS) is a common functional disorder in the gastrointestinal tract. Inflammatory response has been found to participate in the pathogenesis of IBS. This study aimed to explore the effects of long non-coding RNA taurine upregulated gene 1 (TUG1) on tumor necrosis factor alpha (TNF-alpha)-induced interstitial cells of Cajal (ICC) inflammatory injury, which was relevant to the pathogenesis of IBS. PATIENTS AND METHODS: The expression levels of TUG1 and microRNA-127 (miR-127) were analyzed by qRT-PCR. Viability, apoptosis and the expression of apoptosis-associated factors were analyzed by CCK-8 assay, flow cytometry and Western blot, respectively. The mRNA and protein levels of pro-inflammatory cytokines were detected by qRT-PCR and Western blot, respectively. Finally, activations of nuclear factor kappa-B (NF-kappa B) and Notch pathways were evaluated by Western blot. RESULTS: TNF-alpha treatment inhibited ICC viability, induced ICC apoptosis and promoted an inflammatory response in ICC. TUG1 was down regulated in TNF-alpha-treated ICC. TUG1 overexpression protected ICC from TNF-alpha-induced apoptosis and pro-inflammatory cytokines expression. TUG1 suppression showed opposite effects. MiR-127 was negatively regulated by TUG1 and implicated in the action of TUG1 in ICC. MiR-127 up-regulation largely reversed the effects of TUG1 on TNF-alpha-treated ICC. Mechanistically, TUG1 inhibited TNF-alpha-induced activation of NF-kappa B and Notch pathways in ICC by down-regulating miR-127. CONCLUSIONS: TUG1 attenuated TNF-alpha-caused apoptosis and inflammatory response in ICC by down-regulating miR-127 and then inactivating NF-kappa B and Notch pathways.
引用
收藏
页码:312 / 320
页数:9
相关论文
共 37 条
[1]   Is irritable bowel syndrome a low-grade inflammatory bowel disease? [J].
Bercik, P ;
Verdu, EF ;
Collins, SM .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2005, 34 (02) :235-+
[2]   Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome [J].
Camilleri, Michael ;
Lasch, Karen ;
Zhou, Wen .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2012, 303 (07) :G775-G785
[3]   Aquaporins 1, 3 and 8 expression in irritable bowel syndrome rats' colon via NF-κB pathway [J].
Chao, Guanqun ;
Zhang, Shuo .
ONCOTARGET, 2017, 8 (29) :47175-47183
[4]  
Chen C, 2016, AM J TRANSL RES, V8, P2981
[5]  
Chen LJ, 2018, EUR REV MED PHARMACO, V22, P2099, DOI 10.26355/eurrev_201804_14743
[6]   Irritable Bowel Syndrome A Clinical Review [J].
Chey, William D. ;
Kurlander, Jacob ;
Eswaran, Shanti .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (09) :949-958
[7]  
Cipolla Gabriel A, 2018, Noncoding RNA, V4, DOI 10.3390/ncrna4020013
[8]   MicroRNAs in inflammatory bowel disease - pathogenesis, diagnostics and therapeutics [J].
Coskun, Mehmet ;
Bjerrum, Jacob Tveiten ;
Seidelin, Jakob Benedict ;
Nielsen, Ole Haagen .
WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (34) :4629-4634
[9]   Enhanced Cholinergic-Mediated Increase in the Pro-Inflammatory Cytokine IL-6 in Irritable Bowel Syndrome: Role of Muscarinic Receptors [J].
Dinan, Timothy G. ;
Clarke, Gerard ;
Quigley, Eamonn M. M. ;
Scott, Lucinda V. ;
Shanahan, Fergus ;
Cryan, John ;
Cooney, John ;
Keeling, P. W. N. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (10) :2570-2576
[10]  
Ding XW, 2017, EUR REV MED PHARMACO, V21, P5191, DOI 10.26355/eurrev_201711_13839